-

CHEMOCENTRYX SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against ChemoCentryx, Inc. - CCXI

NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 6, 2021 to file lead plaintiff applications in a securities class action lawsuit against ChemoCentryx, Inc. (NasdaqGS: CCXI), if they purchased the Company’s shares between November 26, 2019 and May 3, 2021, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.

What You May Do

If you purchased shares of ChemoCentryx and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgs-ccxi/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by July 6, 2021.

About the Lawsuit

ChemoCentryx and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.

On May 4, 2021, the U.S. Food and Drug Administration issued briefing documents regarding the Company’s drug candidate, avacopan, noting that “[c]omplexities of the study design…raise questions about the interpretability of the data to define a clinically meaningful benefit of avacopan” and that the review had “identified several areas of concern, raising uncertainty about the interpretability of the data and the clinical meaningfulness of these results.”

On this news, shares of ChemoCentryx plummeted approximately 45%, to close at $26.63 per share on May 4, 2021.

The case is Homyk v. ChemoCentryx, Inc., et al., No. 3:21-cv-03343.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking to recover investment losses due to corporate fraud and malfeasance by publicly traded companies. KSF has offices in New York, California and Louisiana.

To learn more about KSF, you may visit www.ksfcounsel.com.

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

Kahn Swick & Foti, LLC

NASDAQ:CCXI

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-877-515-1850

More News From Kahn Swick & Foti, LLC

Soho House Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Sale of Soho House & Co Inc. - SHCO

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the sale of Soho House & Co Inc. (NYSE: SHCO) to affiliates of MCR. Under the terms of the transaction, shareholders of Soho received $9.00 in cash for each share of Soho that they owned. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the considera...

Apollo Global Management, Inc. Securities Fraud Class Action Result of Undisclosed Relationship with Jeffrey Epstein and 16% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until May 1, 2026 to file lead plaintiff applications in a securities class action lawsuit against Apollo Global Management, Inc. (NYSE: APO) (“Apollo” or the “Company”), if they purchased or otherwise acquired the Company’s securities between May 10, 2021 and February 21, 2026, inclu...

Inspire Medical Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Inspire Medical Systems, Inc. - INSP

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Inspire Medical Systems, Inc. (NYSE: INSP). In August of 2025, contrary to the Company’s repeated assurances that it had met all regulatory, technical, and commercial prerequisites for the launch of its Inspire V device, the Company disclosed that the launch faced an "elo...
Back to Newsroom